logo
Twitter
Discord
Email
logo
logo
Phathom Pharmaceuticals, Inc.NASDAQ - PHAT
Reports
Search reports
Name
Reporting Date
Filing Date
2024-09-30 10-Q2024-09-302024-11-07
2024-06-30 10-Q2024-06-302024-08-08
2024-03-31 10-Q2024-03-312024-06-14
2023-12-31 10-K2023-12-312024-06-14
2024-03-31 10-Q2024-03-312024-05-09
2023-12-31 10-K2023-12-312024-03-07
2023-09-30 10-Q2023-09-302023-11-09
2023-06-30 10-Q2023-06-302023-08-10
2023-03-31 10-Q2023-03-312023-05-10
2022-12-31 10-K2022-12-312023-02-28
2022-09-30 10-Q2022-09-302022-11-09
2022-09-30 10-Q2022-09-302022-11-08
2022-06-30 10-Q2022-06-302022-08-02
2022-03-31 10-Q2022-03-312022-05-10
2021-12-31 10-K2021-12-312022-03-01
2021-09-30 10-Q2021-09-302021-11-08
2021-06-30 10-Q2021-06-302021-08-10
2021-03-31 10-Q2021-03-312021-05-11
2020-12-31 10-K2020-12-312021-03-30
2020-09-30 10-Q2020-09-302020-11-10
1
2
20 / page
About
Name
Phathom Pharmaceuticals, Inc.
Overview
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Show More
CEO
Ms. Terrie J. Curran
Industry
Biotechnology
Exchange
NASDAQ
Listing Date
2019-10-25
Address
100 Campus Drive, Suite 102, Florham Park, NJ, 07932, United States
Tel
877-742-8466
Website
https://www.phathompharma.com